Interestingly, the same observation was made for non-diabetic antibody-positive donors that have yet progressed to T1D onset, highlighting the potential benefit of using TNF-α inhibitors in earlier stages of T1D. The gene discussed is TNF; the disease is type 1 diabetes mellitus.